![]()
12
| 4 | 2004
Klinisk Biokemi i Norden
Moller HJ, Davies P, Hampel H. Detection of tau
phosphorylated at threonine 231 in cerebrospinal
fluid of Alzheimer’s disease patients. Neurosci Lett
2000;287:187-190.
Olsson A, Vanderstichele H, Andreasen N,
Vanmechelen E, Blennow K. Simultaneous measu-
rement of
β
-amyloid
(1-42)
, tau and phosphorylated
tau protein in cerebrospinal fluid from Alzheimer
patients. Clin Chem 2004, in press.
Otto M, Wiltfang J, Tumani H, Zerr I, Lantsch M,
Kornhuber J, Weber T, Kretzschmar HA, Poser S.
Elevated levels of tau-protein in cerebrospinal
fluid of patients with Creutzfeldt-Jakob disease.
Neurosci Lett 1997;225:210-212.
Riemenschneider M, Wagenpfeil S, Vanderstichele
H, Otto M, Wiltfang J, Kretzschmar H, Vanmechelen
E, Forstl H, Kurz A. Phospho-tau/total tau ratio in
cerebrospinal fluid discriminates Creutzfeldt-Jakob
disease from other dementias. Mol Psychiatry
2003;8:343-347.
Vanderstichele H, Van Kerschaver E, Hesse C,
Davidsson P, Buyse MA, Andreasen N, Minthon
L, Wallin A, Blennow K, Vanmechelen E.
Standardization of measurement of beta-amy-
loid(1-42) in cerebrospinal fluid and plasma.
Amyloid 2000;7:245-258.
Vanmechelen E, Vanderstichele H, Davidsson P,
Van Kerschaver E, Van der Perre B, Sjögren M,
Andreasen N, Blennow K. Quantification of tau
phosphorylated at threonine 181 in human cere-
brospinal fluid: a sandwich ELISA with a synthetic
phosphopeptide for standardization. Neurosci Lett
2000;285:49-52.
Zetterberg H, Wahlund LO, Blennow K.
Cerebrospinal fluid markers for prediction of
Alzheimer’s disease. Neurosci Lett 2003;352:67-
69.
Island. Foto: Ingunn Torsteinsdottir.
